211 related articles for article (PubMed ID: 22553327)
1. LuIII parvovirus selectively and efficiently targets, replicates in, and kills human glioma cells.
Paglino JC; Ozduman K; van den Pol AN
J Virol; 2012 Jul; 86(13):7280-91. PubMed ID: 22553327
[TBL] [Abstract][Full Text] [Related]
2. Autonomous parvoviruses neither stimulate nor are inhibited by the type I interferon response in human normal or cancer cells.
Paglino JC; Andres W; van den Pol AN
J Virol; 2014 May; 88(9):4932-42. PubMed ID: 24554651
[TBL] [Abstract][Full Text] [Related]
3. Atomic Resolution Structure of the Oncolytic Parvovirus LuIII by Electron Microscopy and 3D Image Reconstruction.
Pittman N; Misseldine A; Geilen L; Halder S; Smith JK; Kurian J; Chipman P; Janssen M; Mckenna R; Baker TS; D'Abramo A; Cotmore S; Tattersall P; Agbandje-McKenna M
Viruses; 2017 Oct; 9(11):. PubMed ID: 29084163
[TBL] [Abstract][Full Text] [Related]
4. Distinct host cell fates for human malignant melanoma targeted by oncolytic rodent parvoviruses.
Vollmers EM; Tattersall P
Virology; 2013 Nov; 446(1-2):37-48. PubMed ID: 24074565
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic parvoviruses: from basic virology to clinical applications.
Marchini A; Bonifati S; Scott EM; Angelova AL; Rommelaere J
Virol J; 2015 Jan; 12():6. PubMed ID: 25630937
[TBL] [Abstract][Full Text] [Related]
6. Species specificity for transduction of cultured cells by a recombinant LuIII rodent parvovirus genome encapsidated by canine parvovirus or feline panleukopenia virus.
Spitzer AL; Maxwell F; Corsini J; Maxwell IH
J Gen Virol; 1996 Aug; 77 ( Pt 8)():1787-92. PubMed ID: 8760427
[TBL] [Abstract][Full Text] [Related]
7. Encapsidation of a recombinant LuIII parvovirus genome by H1 virus and the fibrotropic or lymphotropic strains of minute virus of mice.
Maxwell IH; Long CJ; Carlson JO; Rhode SL; Maxwell F
J Gen Virol; 1993 Jun; 74 ( Pt 6)():1175-9. PubMed ID: 8509766
[TBL] [Abstract][Full Text] [Related]
8. Symmetric-strand packaging of recombinant parvovirus LuIII genomes that retain only the terminal regions.
Corsini J; Carlson JO; Maxwell F; Maxwell IH
J Virol; 1995 Apr; 69(4):2692-6. PubMed ID: 7884925
[TBL] [Abstract][Full Text] [Related]
9. Possible active origin of replication in the double stranded extended form of the left terminus of LuIII and its implication on the replication model of the parvovirus.
Diffoot-Carlo N; Vélez-Pérez L; de Jesús-Maldonado I
Virol J; 2005 May; 2():47. PubMed ID: 15927068
[TBL] [Abstract][Full Text] [Related]
10. [Oncolytic properties of some orthopoxviruses, adenoviruses and parvoviruses in human glioma cells].
Razumov IA; Sviatchenko VA; Protopopova EV; Kochneva GV; Kiselev NN; Gubanova NV; Shilov AG; Mordvinov VA; Netesov SV; Chumakov PM; Loktev VB
Vestn Ross Akad Med Nauk; 2013; (12):4-8. PubMed ID: 24741936
[TBL] [Abstract][Full Text] [Related]
11. Cancer gene therapy through autonomous parvovirus--mediated gene transfer.
Cornelis JJ; Lang SI; Stroh-Dege AY; Balboni G; Dinsart C; Rommelaere J
Curr Gene Ther; 2004 Sep; 4(3):249-61. PubMed ID: 15384939
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-Attenuated Clone of Virulent Semliki Forest Virus Overcomes Antiviral Type I Interferon in Resistant Mouse CT-2A Glioma.
Martikainen M; Niittykoski M; von und zu Fraunberg M; Immonen A; Koponen S; van Geenen M; Vähä-Koskela M; Ylösmäki E; Jääskeläinen JE; Saksela K; Hinkkanen A
J Virol; 2015 Oct; 89(20):10637-47. PubMed ID: 26269187
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic Vascular Endothelial Growth Factor-Blocking Peptides Displayed on the Capsid of an Infectious Oncolytic Parvovirus: Assembly and Immune Interactions.
Grueso E; Sánchez-Martínez C; Calvo-López T; de Miguel FJ; Blanco-Menéndez N; Fernandez-Estevez M; Elizalde M; Sanchez J; Kourani O; Martin D; Tato A; Guerra M; Andrés G; Almendral JM
J Virol; 2019 Oct; 93(19):. PubMed ID: 31315994
[TBL] [Abstract][Full Text] [Related]
14. Pediatric and Adult High-Grade Glioma Stem Cell Culture Models Are Permissive to Lytic Infection with Parvovirus H-1.
Josupeit R; Bender S; Kern S; Leuchs B; Hielscher T; Herold-Mende C; Schlehofer JR; Dinsart C; Witt O; Rommelaere J; Lacroix J
Viruses; 2016 May; 8(5):. PubMed ID: 27213425
[TBL] [Abstract][Full Text] [Related]
15. Activation of a glioma-specific immune response by oncolytic parvovirus Minute Virus of Mice infection.
Grekova SP; Raykov Z; Zawatzky R; Rommelaere J; Koch U
Cancer Gene Ther; 2012 Jul; 19(7):468-75. PubMed ID: 22539062
[TBL] [Abstract][Full Text] [Related]
16. Genome packaging sense is controlled by the efficiency of the nick site in the right-end replication origin of parvoviruses minute virus of mice and LuIII.
Cotmore SF; Tattersall P
J Virol; 2005 Feb; 79(4):2287-300. PubMed ID: 15681430
[TBL] [Abstract][Full Text] [Related]
17. Serologic Cross-reactivity of Murine Parvovirus Capsid Antigens.
Wagner Bs Rlatg AM; Romero-Aleshire Ms PharmD MJ; Billheimer PhD DD; Henderson PhD KS; Besselsen Dvm PhD Daclam Dacvp DG
Comp Med; 2024 May; ():. PubMed ID: 38714354
[TBL] [Abstract][Full Text] [Related]
18. Targeting human glioblastoma cells: comparison of nine viruses with oncolytic potential.
Wollmann G; Tattersall P; van den Pol AN
J Virol; 2005 May; 79(10):6005-22. PubMed ID: 15857987
[TBL] [Abstract][Full Text] [Related]
19. The parvoviral capsid controls an intracellular phase of infection essential for efficient killing of stepwise-transformed human fibroblasts.
Paglino J; Tattersall P
Virology; 2011 Jul; 416(1-2):32-41. PubMed ID: 21600623
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic rat parvovirus H-1PV, a candidate for the treatment of human lymphoma: In vitro and in vivo studies.
Angelova AL; Aprahamian M; Balboni G; Delecluse HJ; Feederle R; Kiprianova I; Grekova SP; Galabov AS; Witzens-Harig M; Ho AD; Rommelaere J; Raykov Z
Mol Ther; 2009 Jul; 17(7):1164-72. PubMed ID: 19367260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
